Immunogenicity of vaccines for malaria-exposed populations

Immunogenicity of vaccines for malaria-exposed populations

<p>An efficacious malaria vaccine will be a necessary tool for malaria eradication, however current vaccine candidates have only demonstrated a moderate level of short-term efficacy. Additionally, these vaccines often display reduced immunogenicity and efficacy in the malaria-exposed target po...

Bibliografski detalji
Glavni autor:	Bowyer, GSA
Daljnji autori:	Hill, A
Format:	Disertacija
Jezik:	English
Izdano:	2018
Teme:	Ebola Immunology Vaccines Malaria

Slični predmeti

Prospects for enhancing malaria vaccine efficacy by combining pre-erythrocytic antigens
od: Atcheson, E
Izdano: (2017)

Towards improved blood-stage malaria vaccines: characterising the underlying immunogenicity of vaccine adjuvants and vectors
od: de Cassan, S
Izdano: (2011)

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
od: Daniela Manno, i dr.
Izdano: (2023-08-01)

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans
od: Chelsea McLean, i dr.
Izdano: (2023-09-01)

Investigating protective mechanisms of anti-sporozoite vaccines
od: Bellamy, DG
Izdano: (2023)

Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection
od: Brandon Sack, i dr.
Izdano: (2017-05-01)

Ebola vaccine 2014: remained problems to be answered
od: Somsri Wiwanitkit, i dr.
Izdano: (2015-02-01)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
od: Jennifer K. Legardy-Williams, i dr.
Izdano: (2020-03-01)

Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial
od: Julie A. Ake, i dr.
Izdano: (2024-05-01)

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)
od: Conall H. Watson, i dr.
Izdano: (2024-11-01)

Progress with new malaria vaccines
od: Webster Daniel, i dr.
Izdano: (2003-01-01)

Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges
od: Sumira Malik, i dr.
Izdano: (2023-01-01)

Insights into the design of an improved PfRH5 malaria immunogen using vaccine-induced monoclonal antibodies
od: Alanine, DGW
Izdano: (2017)

Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions
od: Linda Bus-Jacobs, i dr.
Izdano: (2024-04-01)

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
od: I. V. Dolzhikova, i dr.
Izdano: (2017-03-01)

Ebola vaccine uptake and attitudes among healthcare workers in North Kivu, Democratic Republic of the Congo, 2021
od: Reena H. Doshi, i dr.
Izdano: (2023-07-01)

Novel malaria vaccines
od: Matthew B. Laurens
Izdano: (2021-11-01)

The Merits of Malaria Diagnostics during an Ebola Virus Disease Outbreak
od: Emmie de Wit, i dr.
Izdano: (2016-02-01)

Impact of Dietary Protein Restriction on the Immunogenicity and Efficacy of Whole-Sporozoite Malaria Vaccination
od: Helena Nunes-Cabaço, i dr.
Izdano: (2022-04-01)

Malaria pre-erythrocytic stage vaccines: targeting antigen combinations
od: Bauza, K
Izdano: (2012)

Background malaria incidence and parasitemia during the three-dose RTS,S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria
od: Griffin J Bell, i dr.
Izdano: (2023-10-01)

New approaches to pre-erythrocytic malaria vaccination
od: Mukhopadhyay, E
Izdano: (2021)

Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine
od: Brian Greenwood, i dr.
Izdano: (2017-05-01)

Modulation of receptor for advanced glycation end products signal transduction pathway as therapeutic option for malaria therapy
od: Chuah, Yaw Kuang
Izdano: (2015)

Humoral antimalaria immune response in Nigerian children exposed to helminth and malaria parasites
od: Selorme Adukpo, i dr.
Izdano: (2022-09-01)

The Immunogenicity of a VLP-based Malaria Vaccine Targeting CSP in Pregnant and Neonatal Mice
od: Lucie Jelínková, i dr.
Izdano: (2023-01-01)

APPROACHING THE TARGET: THE PATH TOWARDS AN EFFECTIVE MALARIA VACCINE
od: Alberto L. García-Basteiro, i dr.
Izdano: (2012-03-01)

APPROACHING THE TARGET: THE PATH TOWARDS AN EFFECTIVE MALARIA VACCINE
od: Alberto L. García-Basteiro, i dr.
Izdano: (2012-01-01)

Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
od: Aroosa Younis Nadeem, i dr.
Izdano: (2022-04-01)

Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials
od: Juntao Yin, i dr.
Izdano: (2024-12-01)

Malaria vaccine coverage estimation using age-eligible populations and service user denominators in Kenya
od: Angela K. Moturi, i dr.
Izdano: (2023-09-01)

Comparison between survival and severe models of malaria infection for better understanding of the underlying disease pathogenesis
od: Chong, Wing Chui
Izdano: (2013)

Health Precautions Taken by Travelers to Countries with Ebola Virus Disease
od: Ifeoma Ezeoke, i dr.
Izdano: (2016-05-01)

Adherence to Ebola-specific malaria case management guidelines at health facilities in Guinea during the West African Ebola epidemic
od: Ian Hennessee, i dr.
Izdano: (2018-06-01)

Liver-stage vaccines for malaria
od: Longley, RJ
Izdano: (2013)

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial
od: Victorine A. Mensah, i dr.
Izdano: (2017-11-01)

One hundred malaria attacks since birth. A longitudinal study of African children and young adults exposed to high malaria transmissionResearch in context
od: Jean-François Trape, i dr.
Izdano: (2024-01-01)

Malaria vaccine development: State of the art and beyond
od: Shuyang Guo, i dr.
Izdano: (2021-01-01)

Chemically augmented malaria sporozoites display an altered immunogenic profile
od: Nikolas Duszenko, i dr.
Izdano: (2023-08-01)

Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus
od: Kuldeep Dhama, i dr.
Izdano: (2018-08-01)